Shares of BioTelemetry, Inc. (NASDAQ:BEAT) have earned an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $43.50.
BEAT has been the topic of several analyst reports. BidaskClub raised shares of BioTelemetry from a “strong sell” rating to a “sell” rating in a report on Tuesday, December 19th. Zacks Investment Research lowered shares of BioTelemetry from a “hold” rating to a “strong sell” rating in a report on Thursday, November 2nd. SunTrust Banks initiated coverage on shares of BioTelemetry in a report on Monday, October 23rd. They issued a “buy” rating and a $41.00 target price on the stock. Dougherty & Co reaffirmed a “buy” rating and issued a $40.00 target price on shares of BioTelemetry in a report on Wednesday, November 8th. Finally, Raymond James Financial initiated coverage on shares of BioTelemetry in a report on Thursday, October 26th. They issued an “outperform” rating and a $37.00 target price on the stock.
BioTelemetry (BEAT) traded up $0.90 on Tuesday, hitting $32.55. 284,500 shares of the stock traded hands, compared to its average volume of 418,293. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. BioTelemetry has a fifty-two week low of $23.30 and a fifty-two week high of $39.20. The company has a market cap of $1,025.72, a price-to-earnings ratio of 25.23, a price-to-earnings-growth ratio of 1.41 and a beta of 0.67.
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.